|
Sr.
No.
|
Project
Title
|
Year
|
Duration
|
Sample
size
|
Indication
|
| 1 |
A randomised, double
blind, placebo controlled study of an Herbal
Ayurvedic formulation in patients with active
Rheumatoid arthritis. [ abstract
/ request copy] |
1994 |
16
weeks |
182 |
RA |
| 2 |
A single blind, long
term clinical trial of dose related efficacy,
of RA-11 (Native Indian Ayurvedic preparation)
in the treatment of Rheumatoid arthritis
and its effect on IL-6 and toxicity.
|
1995 |
16
weeks |
100 |
RA |
| 3 |
A randomized, double
blind placebo controlled evaluation of RA-11
(Artrex), in patients with symptomatic Osteoarthritis.
[ abstract
/ request copy] |
1995-1996 |
32
weeks |
90 |
OA |
| 4 |
A randomised, double
blind, multicentric study, to document the
efficacy, safety and tolerability of Meloxicam
in comparison to Piroxicam in patients suffering
from Rheumatoid Arthritis. [ abstract
/ request copy] |
1998 |
4
weeks |
121 |
RA |
| 5 |
A randomized, double
blind, multicentric study, to document the
Efficacy, safety and tolerability of Meloxicam
in comparison to Diclofenac Sodium in patients
suffering from Osteoarthritis. [ abstract
/ request copy] |
1998 |
4
weeks |
133 |
OA |
| 6 |
A randomized, double blind,
multicentric study, to document the efficacy,
safety and tolerability of Rofecoxib in
comparison to Diclofenac in patients suffering
from Osteoarthritis.
[abstract
/ request copy]
|
2000
|
4
weeks |
60 |
OA |
| 7 |
A randomized, double
blind, multicentric study, to document the
efficacy, safety and tolerability of Celecoxib
in comparison to Piroxicam in Indian patients
suffering from Rheumatoid arthritis.
|
1999 |
4
weeks |
50 |
RA |
| 8 |
A randomised, double
blind, multicentric study, to compare the
efficacy, safety and tolerability of Rofecoxib
Betacyclodextrin with Rofecoxib in patients
with Rheumatoid arthritis.
|
2002 |
4
weeks |
86 |
RA |
| 9 |
A randomized, double
blind, multicentric study, to document the
efficacy, safety and tolerability of Rofecoxib
Betacyclodextrin in comparison to Rofecoxib
in patients suffering from Osteoarthritis.
[ abstract
/ request copy] |
2002
|
4
weeks |
86 |
OA |
| 10 |
A prospective, randomised,
double blind placebo controlled phase III
multicentric study to evaluate the efficacy
and safety of IRA-01(Ayurvedic derived multiplant
drug) in patients with Rheumatoid arthritis.
[ abstract
/ request copy] |
2002-2003 |
24
weeks |
130 |
RA |
| 11 |
A controlled study to
test the efficacy and safety profile of
IRA-01(Ayurvedic derived multiplant drug)
in an open label phase: A follow up of the
IRA-01 randomized drug trial. [ abstract
/ request copy] |
2002-2003 |
24
weeks |
62 |
RA |
| 12 |
A Randomized, Double
Blind, Platform based multiplant formulation,
Multicentric Study To Evaluate The Efficacy
And Safety Of N1 (Ayurvedic) and further
compare them to Glucosamine Sulfate and
placebo in patients with symptomatic Osteoarthritis
of the Knees; a 7 arm multicentric study.
( NMITLI Project) |
2003 |
16
weeks |
245 |
OA |
| 13 |
A Study to evaluate the
Efficacy And Safety of a proprietary multiplant
Ayurvedic formulation in patients with Osteoarthritis
Knees. ( NMITLI Project) |
2004 |
16
weeks |
121 |
OA |
| 14 |
A Study to evaluate B1-(an
Ayurvedic formulation) for efficacy and
safety and compare it to K1 – (Ayurvedic
proprietary formulation) and N3 (multiplant
Ayurvedic formulation) in patients with
symptomatic Osteoarthritis (OA) of the Knees.
( NMITLI Project) |
2004 |
16
weeks |
108 |
OA |
| 15 |
An open label, Ayurvedic
comparator controlled study to further evaluate
the efficacy of N3 (a multiplant Ayurvedic
formulation) in patients with Osteoarthritis
Knees. ( NMITLI Project) |
2004 |
16
weeks |
49 |
OA |
| 16 |
A Randomized, Double
Blind comparator controlled multicentric
study to evaluate the efficacy and Safety
of B1 (a single plant Ayurvedic formulation)
and compare it with Ayurvedic proprietary
formulation and Hydroxychloroquine sulphate
in patients with active Rheumatoid Arthritis.
( NMITLI Project) |
2003-2004 |
24
weeks |
126 |
RA |
| 17 |
A crossover study to
evaluate the efficacy of B1 (Single plant
Ayurvedic formulation) patients with Rheumatoid
Arthritis; a follow up of the randomized
double blind 3 limb study of B1. ( NMITLI
Project) |
2004-2005
|
24
weeks |
48 |
RA |
| 18 |
An Open label clinical
study to evaluate dose searching activity
of B2 (Single plant Ayurvedic formulation)
and safety in patients with symptomatic
Osteoarthritis of the Knees. ( NMITLI
Project) |
2004 |
6
weeks |
15 |
OA |
| 19 |
A Phase III, 12 weeks,
Multicentre, Double-Blind Randomized, Placebo-and
Active Comparator-Controlled, Parallel Group
Study to investigate the efficacy and safety
of GW406381, 5 mg, 10 mg, 25 mg, and 50
mg administered orally once daily, in Adults
with Rheumatoid arthritis. .
|
2005 - 2006 |
13
weeks |
84 |
RA |
| 20 |
A Randomized, double-blind,
parallel group, placebo controlled, prospective,
pilot study to evaluate the efficacy and
safety of TNF alpha inhibitor SPHIRA in
patients of active rheumatoid arthritis
with inadequate response to Methotrexate.
|
2006-2007 |
24
weeks |
80 |
RA |
| 21 |
A Phase III equivalence
drug trial for evaluation of efficacy and
safety of SGPF 'C' (an oral standardized
herbal preparation) and SGPF 'C' plus (with
GI) in patients with syptomatic osteoarthritis
Knees: A randomized, double blind comparison
with Oral Celecoxib and Glucosamine.
|
2006-2007 |
24
weeks |
440 |
OA |
| 22 |
Efficacy
and Safety of Nimesulide Extended Release
Tablets in Symptomatic Treatment of Osteoarthritis
Knee: A Double Blind Randomized Controlled
Comparison with Placebo and Diclofenac Sustained
Release Tablets |
2007-2008 |
12
weeks |
133 |
OA |
| 23 |
A
randomised, open label, four arms parallel
study to evaluate the safety & efficacy of
anti-CD6 monoclonal antibody (TihmAb) in combination
with Methotrexate in patients with active
rheumatoid arthritis |
2008 |
24
weeks |
30 |
RA |
| 24 |
Multi-National
Open-Label Study to Evaluate the Safety, Tolerability
and Efficacy of Tocilizumab in Patients with
Active Rheumatoid Arthritis on Background
Non-biologic DMARDs who have an Inadequate
Response to Current Non-biologic DMARD and/or
Anti-TNF Therapy. |
2009-2010 |
24
WEEKS |
5 |
RA |
| 25 |
An
Open Label, Prospective Clinical Study to
Evaluate The Efficacy and safety of TLPL/AY/03/2008
in Patients suffering from Osteoarthritis
of the Knee(s) |
2009-2010 |
24
WEEKS |
40 |
OA |
| 26 |
Phase
3 Randomized, Double-Blind, Placebo-Controlled
Study of the Efficacy and Safety of 2 Doses
of CP-690,550 in Patients with Active Rheumatoid
Arthritis on Background Methotrexate |
2009 |
2
YEARS |
23 |
RA |
| 27 |
Phase
3, Randomized, Double-Blind, Placebo-Controlled
Study of the Efficacy and Safety of 2 Doses
of CP-690,550 Monotherapy in Patients with
Active Rheumatoid Arthritis |
2009-2010 |
24
WEEKS |
12 |
RA |
| 28 |
An
Open label,balanced randomized,Multiple –dose
Two –period,Two- treatment,Two-sequence,Steady
state, Crossover Comparative Bioequivalence
Study of Two Formulations of Azathioprine
in Adult Patients with Rheumatoid Arthritis
(RA) |
2009-2010 |
14
DAYS |
20 |
RA |
| 29 |
A
Long Term,Open-Label Follow-Up Study of CP-690,550,A
Moderately Selective Janus-Kinase-3 Inhibitor,
For Treatment Of Rheumatoid Arthritis. |
2010 |
5YEARS |
41 |
RA |
| 30 |
A
Non Interventional Study to Understand Disease
characteristics with Regards to Presenting
Features, Demographics, Disease Duration,
Basis of Diagnosis and Treatment Paradigms
in Rheumatoid Arthritis
|
2011 |
9
months |
15 |
RA |
| 31 |
A
Randomised,double-blind,placebo controlled,multicenter,two-part,dose
ranging and confirmatory study with an operationally
seamless design,evaluating efficacy and safety
of SAR153191 on top of methotrexate (MTX)
in patients with active rheumatoid arthritis
who are inadequate responders to MTX therapy. |
2012-2013 |
1
YEAR |
8 |
RA |
| 32 |
A
Phase 3,Randomised,Double-Blind,Active Comparator
Study of the efficacy and Safety of R-TPR-015(1422015)
in patients with Active Rheumatoid Arthritis
on a stable dose of Methotrexate. |
2012-2013 |
58
WEEKS
|
24 |
RA |
